ALS and Medical Aid in Dying: The Challenges of Timing

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gherig's disease, presents a particular challenge: the window for self-administration can close before patients are able to use it. 

Of all the terminal diagnoses, ALS requires perhaps the most careful planning around timing. Not because the process itself is more complicated — though sometimes it is — but because of a fundamental tension built into the disease: the ability to self-administer the aid in dying medication depends on physical capacities that ALS progressively destroys. By the time a patient becomes eligible for medical aid in dying, the ability to self-administer the medications may be severely compromised, or lost entirely.

For most terminal illnesses, the question of timing is about legal and logistical preparation. For ALS, it is also about biology. The window in which aid in dying remains legally and physically possible may be narrower than the patient expects — and it may close without warning.

The Self-Administration Requirement

Under the NY Medical Aid in Dying Act, the patient must self-administer the medication. This is not optional and it is not a formality. No one may administer the medication to the patient on their behalf — not a nurse, not a family member, not a physician. The patient must be physically capable of taking the medication themselves.

For most people with cancer, organ failure, or many other terminal conditions, this requirement does not pose a significant challenge. The patient is alert and capable, and the physical act of taking medication is within reach, sometimes until quite late in the disease course.

For ALS patients, this requirement is central to everything. ALS progressively destroys motor function. Eventually — and the timeline varies greatly from person to person — swallowing becomes impaired, hand function is lost, and the physical acts required to self-administer become impossible. Once that line is crossed, medical aid in dying is no longer an option.

Two Trajectories, Two Different Clocks

ALS does not follow a single path. Bulbar-onset ALS, which begins with the muscles of speech and swallowing, tends to affect oral function early. Patients with bulbar-onset ALS may find that their ability to swallow becomes compromised within months of diagnosis. For these patients, the window for medical aid in dying can close surprisingly quickly.

Limb-onset ALS, which begins with weakness in the arms or legs, typically preserves swallowing function longer. But it affects hand and arm strength, which is relevant to whether a patient can physically initiate ingestion without assistance. Each patient's situation is individual, and clinical assessment by someone familiar with aid in dying protocols is essential.

What both trajectories share is this: at some point, the window closes. And because ALS progression can accelerate unpredictably — sometimes dramatically and quickly after a period of relative stability — waiting to “see how things go" before starting the medical aid in dying process is a risk.

Feeding Tubes and the Ingestion Question

Some ALS patients have a percutaneous endoscopic gastrostomy (PEG) tube placed when swallowing becomes unsafe. This raises a practical question that families ask us often: if the patient has a feeding tube, does that change the self-administration options?

The answer involves clinical nuance. Quiĕtus works with Daniel Cogan, our nurse practitioner, and the patient's attending physician to assess each case individually. The fundamental legal requirement — self-administration — does not change. Whether orally, via PEG, or rectally, the question remains as to whether the patient retains the ability to self-administer aid in dying medications.

This is not a question to leave until the feeding tube is placed. It should be part of the planning conversation early in the process, so that all parties — patient, family, clinicians — understand what the pathway looks like as the disease progresses.

What We Recommend for ALS Patients

We recommend to start thinking about these issues sooner rather than later, as daunting as they may be. The earlier this conversation begins, the more time there is to complete the legal process, assess the clinical trajectory, and build a plan that gives the individual the greatest range of choice for the longest possible time.

Beginning the process early does not mean you have decided to use aid in dying. It does not mean you have given up. It means you are keeping your options open. Many ALS patients who complete the process never use the medication — or use it much later than they expected. But the ones who waited too long to start, and lost access to an option that mattered to them, could not go back.

If you or someone you love has been diagnosed with ALS, we welcome the conversation. We will tell you honestly what the process involves, what the timeline looks like, and what questions you should be asking now.

 This post was reviewed and verified by Daniel Cogan, NP